艰难梭菌DNA聚合酶IIIC：抗菌化合物活性的基础
Clostridium difficile DNA polymerase IIIC: basis for activity of antibacterial compounds.
作者信息
Torti Andrea, Lossani Andrea, Savi Lida, Focher Federico, Wright George Edward, Brown Neal Curtis, Xu Wei-Chu
机构信息
Istituto di Genetica Molecolare, Consiglio Nazionale delle Ricerche, I-27100 Pavia, Italy.
出版信息
Curr Enzym Inhib. 2011 Oct;7(3):147-153. doi: 10.2174/157340811798807597.
Abstract
Based on the finding that aerobic Gram-positive antibacterials that inhibit DNA polymerase IIIC (pol IIIC) were potent inhibitors of the growth of anaerobic Clostridium difficile (CD) strains, we chose to clone and express the gene for pol IIIC from this organism. The properties of the recombinant enzyme are similar to those of related pol IIICs from Gram-positive aerobes, e.g. B. subtilis. Inhibitors of the CD enzyme also inhibited B. subtilis pol IIIC, and were competitive with respect to the cognate substrate 2'-deoxyguanosine 5'-triphosphate (dGTP). Significantly, several of these inhibitors of the CD pol IIIC had potent activity against the growth of CD clinical isolates in culture.
摘要
基于抑制DNA聚合酶IIIC（pol IIIC）的需氧革兰氏阳性抗菌剂是艰难梭状芽孢杆菌（CD）厌氧菌株生长的有效抑制剂这一发现，我们选择克隆并表达该生物体中pol IIIC的基因。重组酶的特性与革兰氏阳性需氧菌（如枯草芽孢杆菌）中相关的pol IIIC相似。CD酶的抑制剂也抑制枯草芽孢杆菌的pol IIIC，并且相对于同源底物2'-脱氧鸟苷5'-三磷酸（dGTP）具有竞争性。值得注意的是，这些CD pol IIIC抑制剂中的几种对培养中的CD临床分离株的生长具有强效活性。
相似文献
1
Clostridium difficile DNA polymerase IIIC: basis for activity of antibacterial compounds.艰难梭菌DNA聚合酶IIIC：抗菌化合物活性的基础
Curr Enzym Inhib. 2011 Oct;7(3):147-153. doi: 10.2174/157340811798807597.
2
Synthesis of substituted 6-anilinouracils and their inhibition of DNA polymerase IIIC and Gram-positive bacterial growth.取代6-苯胺基尿嘧啶的合成及其对DNA聚合酶IIIC和革兰氏阳性菌生长的抑制作用。
J Med Chem. 2003 Jun 19;46(13):2731-9. doi: 10.1021/jm020591z.
3
A method to assay inhibitors of DNA polymerase IIIC activity.一种检测DNA聚合酶IIIC活性抑制剂的方法。
Methods Mol Med. 2008;142:25-36. doi: 10.1007/978-1-59745-246-5_3.
4
Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.一种新型苯胺基嘧啶-氟喹诺酮杂合化合物的抗菌活性及作用机制
Antimicrob Agents Chemother. 2007 Jan;51(1):119-27. doi: 10.1128/AAC.01311-05. Epub 2006 Oct 30.
5
Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections.DNA 聚合酶 III 抑制剂的发现和开发，用于治疗革兰氏阳性感染。
Bioorg Med Chem. 2019 Aug 1;27(15):3209-3217. doi: 10.1016/j.bmc.2019.06.017. Epub 2019 Jun 11.
6
7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity.7-烷基-N(2)-取代的 3-去氮鸟嘌呤。合成、DNA 聚合酶 III 抑制和抗菌活性。
Bioorg Med Chem Lett. 2011 Jul 15;21(14):4197-202. doi: 10.1016/j.bmcl.2011.05.093. Epub 2011 May 30.
7
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.混合抗菌剂。DNA聚合酶-拓扑异构酶抑制剂。
J Med Chem. 2006 Feb 23;49(4):1455-65. doi: 10.1021/jm0510023.
8
Antimicrobials targeted to the replication-specific DNA polymerases of gram-positive bacteria: target potential of dnaE.针对革兰氏阳性菌复制特异性DNA聚合酶的抗菌药物：dnaE的靶点潜力
Infect Disord Drug Targets. 2012 Oct;12(5):327-31. doi: 10.2174/187152612804142279.
9
Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils.3-取代-6-(3-乙基-4-甲基苯胺基)尿嘧啶的合成及抗菌活性
J Med Chem. 2005 Nov 3;48(22):7063-74. doi: 10.1021/jm050517r.
10
Butylphenyl dGTP: a selective and potent inhibitor of mammalian DNA polymerase alpha.丁基苯基dGTP：一种对哺乳动物DNA聚合酶α具有选择性和强效的抑制剂。
Nucleic Acids Res. 1984 Apr 25;12(8):3695-706. doi: 10.1093/nar/12.8.3695.
引用本文的文献
1
How to spare gut microbiota from antibiotic effects? PK-PD based innovative strategies, target specificity, and molecule-to-medicinal properties.如何使肠道微生物群免受抗生素影响？基于药代动力学-药效学的创新策略、靶点特异性及从分子到药物的特性。
RSC Med Chem. 2025 Sep 3. doi: 10.1039/d5md00591d.
2
The impact of ibezapolstat and other infection-relevant antibiotics on the microbiome of humanized mice.伊贝扎泊司他及其他与感染相关抗生素对人源化小鼠微生物组的影响。
Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0160424. doi: 10.1128/aac.01604-24. Epub 2025 Feb 25.
3
The microbiome-restorative potential of ibezapolstat for the treatment of infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae.通过毛螺菌科和颤螺菌科中的变异型PolC型DNA聚合酶III预测了伊贝扎泊司他治疗感染的微生物群恢复潜力。
Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0167924. doi: 10.1128/aac.01679-24. Epub 2025 Feb 21.
4
Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.对抗抗菌药物耐药性：抗菌研究中的创新药物
Angew Chem Int Ed Engl. 2025 Mar 3;64(10):e202414325. doi: 10.1002/anie.202414325. Epub 2025 Feb 10.
5
Identification of the Unwinding Region in the Chromosomal Origin of Replication.染色体复制起点解旋区域的鉴定
Front Microbiol. 2020 Oct 2;11:581401. doi: 10.3389/fmicb.2020.581401. eCollection 2020.
6
Investigational Treatment Agents for Recurrent Infection (rCDI).复发性感染（rCDI）的研究性治疗药物
J Exp Pharmacol. 2020 Oct 9;12:371-384. doi: 10.2147/JEP.S242959. eCollection 2020.
7
Genome Location Dictates the Transcriptional Response to PolC Inhibition in .基因组位置决定了对 PolC 抑制的转录反应。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01363-18. Print 2019 Feb.
8
DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens.作为耐药性细菌病原体抗菌药物潜在靶点的DNA复制蛋白
J Antimicrob Chemother. 2017 May 1;72(5):1275-1284. doi: 10.1093/jac/dkw548.
9
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.艰难梭菌感染治疗方法的研究进展：临床和药物化学综述。
Curr Top Med Chem. 2014;14(1):152-75. doi: 10.2174/1568026613666131113154753.
10
A novel agent effective against Clostridium difficile infection.一种新型有效对抗艰难梭菌感染的药物。
Antimicrob Agents Chemother. 2012 Mar;56(3):1624-6. doi: 10.1128/AAC.06097-11. Epub 2011 Dec 27.
本文引用的文献
1
7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity.7-烷基-N(2)-取代的 3-去氮鸟嘌呤。合成、DNA 聚合酶 III 抑制和抗菌活性。
Bioorg Med Chem Lett. 2011 Jul 15;21(14):4197-202. doi: 10.1016/j.bmcl.2011.05.093. Epub 2011 May 30.
2
Structure of PolC reveals unique DNA binding and fidelity determinants.PolC的结构揭示了独特的DNA结合和保真度决定因素。
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20695-700. doi: 10.1073/pnas.0809989106. Epub 2008 Dec 23.
3
Clostridium difficile--more difficult than ever.艰难梭菌——比以往任何时候都更难对付。
N Engl J Med. 2008 Oct 30;359(18):1932-40. doi: 10.1056/NEJMra0707500.
4
Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005.2000 - 2005年美国成人艰难梭菌相关住院率及病死率上升情况
Emerg Infect Dis. 2008 Jun;14(6):929-31. doi: 10.3201/eid1406.071447.
5
A method to assay inhibitors of DNA polymerase IIIC activity.一种检测DNA聚合酶IIIC活性抑制剂的方法。
Methods Mol Med. 2008;142:25-36. doi: 10.1007/978-1-59745-246-5_3.
6
Update on the changing epidemiology of Clostridium difficile-associated disease.艰难梭菌相关性疾病不断变化的流行病学最新情况
Nat Clin Pract Gastroenterol Hepatol. 2008 Jan;5(1):40-8. doi: 10.1038/ncpgasthep1029.
7
The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome.多重耐药的人类病原体艰难梭菌拥有高度可移动的镶嵌基因组。
Nat Genet. 2006 Jul;38(7):779-86. doi: 10.1038/ng1830. Epub 2006 Jun 25.
8
Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils.3-取代-6-(3-乙基-4-甲基苯胺基)尿嘧啶的合成及抗菌活性
J Med Chem. 2005 Nov 3;48(22):7063-74. doi: 10.1021/jm050517r.
9
Active site directed inhibitors of replication-specific bacterial DNA polymerases.复制特异性细菌DNA聚合酶的活性位点定向抑制剂。
Bioorg Med Chem Lett. 2005 Feb 1;15(3):729-32. doi: 10.1016/j.bmcl.2004.11.016.
10
Synthesis of substituted 6-anilinouracils and their inhibition of DNA polymerase IIIC and Gram-positive bacterial growth.取代6-苯胺基尿嘧啶的合成及其对DNA聚合酶IIIC和革兰氏阳性菌生长的抑制作用。
J Med Chem. 2003 Jun 19;46(13):2731-9. doi: 10.1021/jm020591z.
Zotero 插件